vii) Participants must have had at least 1, but not more than 3 prior systemic therapies for NSCLC. Maintenance, adjuvant, or neoadjuva nt (chemotherapy or chemoradiation) therapy do not count as an additional line of treatment. d) PRC i) Participants must have histologic or cytologic confirmation of adenocarcinoma of the prostate. ii)“Not applicable as per revised protocol 02” Participants have been treated by orchiectomy or are receiving a luteinizing hormone-releasing hormone analog, and have a testosterone level ≤50 ng/dL. iii)“Not applicable as per revised protocol 02” Metastatic disease by any 1 of the following modalities: computerized tomography (CT), magnetic resonance imaging (MRI), and bone scan.